Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 2.84
- Piotroski Score 5.00
- Grade Neutral
- Symbol (DGX)
- Company Quest Diagnostics Incorporated
- Price $156.20
- Changes Percentage (0.66%)
- Change $1.02
- Day Low $155.43
- Day High $157.01
- Year High $160.95
Quest Diagnostics Incorporated provides diagnostic testing, information, and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine testing, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It offers diagnostic information services primarily under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum brands to patients, clinicians, hospitals, independent delivery networks, health plans, employers, direct contract entities, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile paramedics, nurses, and other health and wellness professionals. The company also provides risk assessment services for the life insurance industry; and healthcare organizations and clinicians robust information technology solutions. Quest Diagnostics Incorporated was founded in 1967 and is headquartered in Secaucus, New Jersey.
- Last Earnings 08/14/2024
- Ex-Dividend for 5/16 Dividend 10/04/2024
- Dividend Payable 10/21/2024
- Today N/A
- Next Earnings (Estimated) 01/29/2025
- Fiscal Year End N/A
- Average Stock Price Target $165.00
- High Stock Price Target $190.00
- Low Stock Price Target $140.00
- Potential Upside/Downside N/A
- Consensus Rating Neutral
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) $7.43
- Trailing P/E Ratio 19.16
- Forward P/E Ratio 19.16
- P/E Growth 19.16
- Net Income $854.00 M
Income Statement
Quarterly
Annual
Latest News of DGX
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Decoding Quest Diagnostics Inc (DGX): A Strategic SWOT Insight
Quest Diagnostics Inc (NYSE:DGX) filed its 10-Q report on October 23, 2024, showcasing strong financial performance driven by diagnostic insights. With strategic acquisitions and a focus on revenue di...
By Yahoo! Finance | 2 weeks ago -
Quest Diagnostics Inc (DGX) Q3 2024 Earnings Call Highlights: Strong Revenue Growth Amid ...
The business expects 3% organic growth in 2025, driven by strong utilization trends. The LifeLabs acquisition may slightly impact margins in the short term but is projected to align with Quest's margi...
By Yahoo! Finance | 2 weeks ago -
Quest Diagnostics Incorporated (DGX) Stock Forecasts
David H. Toung is a Senior Analyst at Argus, specializing in Medical Devices & Healthcare Services. With over 20 years of experience in financial analysis, he has worked for notable firms and media ou...
By Yahoo! Finance | 3 months ago
